What is the primary treatment strategy for unstable angina or NSTEMI?

The primary treatment strategy for unstable angina or NSTEMI focuses on preventing further clot formation and managing the increased risk of myocardial infarction. Antiplatelet and anticoagulation therapy plays a critical role in this approach.

In the context of unstable angina and NSTEMI, there is an underlying issue with blood flow due to potential coronary artery thrombosis. Antiplatelet agents, such as aspirin and newer agents like clopidogrel or ticagrelor, help inhibit platelet aggregation. This is crucial for improving coronary blood flow and preventing the progression of ischemia. Alongside antiplatelet therapy, anticoagulation with agents like heparin helps decrease the clotting tendency, further reducing the risk of thrombus formation in the coronary arteries.

While other options such as oxygen therapy may be helpful in certain patients with hypoxemia and morphine sulfate can be beneficial for pain relief, they do not directly address the underlying pathophysiology of unstable angina or NSTEMI. Fibrinolytic therapy is also not indicated in NSTEMI as it is typically reserved for STEMI, where immediate reperfusion is needed. Therefore, focusing on antiplatelet and anticoagulation therapy aligns with the goal of